ergosta-5,7-dienol

Ergosta-5,7-dienol, chemically known as ergosta-5,7-dien-3β-ol, is a sterol intermediate in the ergosterol biosynthesis pathway of fungi and yeasts. Structurally, it belongs to the class of hydroxysterols with a C28 skeleton and two double bonds at the 5 and 7 positions. Its CAS registry is 516-79-0, and it can be referred to by several synonyms including 22,23-dihydroergosterol and Δ5,7-ergostadienol. Unlike cholesterol in animals, fungal cells do not synthesize cholesterol; instead, they produce ergosterol as their major membrane sterol. Ergosta-5,7-dienol is a precursor in the biochemical sequence that ultimately yields ergosterol and can be transformed under UV irradiation to provitamin D4 in certain mushrooms. From a biochemical standpoint, ergosta-5,7-dienol is formed after the initial stages of isoprenoid and squalene synthesis and before the final desaturation steps to ergosterol. In Saccharomyces cerevisiae, for example, deletion or mutation of enzymes such as Δ22-desaturase results in the accumulation of ergosta-5,7-dienol, underscoring its position as a metabolic intermediate. Biotechnological research has exploited this property to produce higher yields of ergosta-5,7-dienol for scientific study or use as precursors in synthetic pathways. Ergosta-5,7-dienol’s role in human nutrition, however, is not characterized by nutrient requirements or dietary reference intakes, as it is not recognized as an essential nutrient for human metabolic function.

Unlike essential nutrients such as vitamins or minerals, ergosta-5,7-dienol does not have defined biological functions in human physiology. Its primary role is within fungal biology rather than human nutrition. In fungi, ergosta-5,7-dienol acts as an intermediate in the biosynthesis of ergosterol, the primary sterol in fungal cell membranes that plays a role analogous to cholesterol in animal cells. Ergosterol is essential for maintaining membrane fluidity and integrity, and ergosta-5,7-dienol is part of the pathway leading to its formation. Research in microbiology and metabolic engineering has focused on manipulating the ergosterol synthesis pathway in yeasts such as Saccharomyces cerevisiae to accumulate ergosta-5,7-dienol for study or industrial precursor use. From a potential human health perspective, ergosta-5,7-dienol itself has not been established to confer direct health benefits at physiologically relevant intake levels. Some research on sterols in mushrooms, including compounds closely related to ergosta-5,7-dienol, has suggested that fungal sterols may contribute to food functionality due to their structural similarity to cholesterol, but these are minor components within the broader spectrum of sterols. The focus of such investigations has typically been on the major sterol ergosterol, which under ultraviolet light can convert to provitamin D2, contributing to vitamin D activity in foods. Ergosta-5,7-dienol has been identified as a precursor to provitamin D4 when exposed to UV light, indicating that exposure of certain mushrooms to UV radiation can produce vitamin D4 alongside vitamin D2, which might have implications for nutritional vitamin D content in foods, particularly plant-based diets. In experimental models, engineered yeasts with altered sterol biosynthesis pathways accumulate ergosta-5,7-dienol, illustrating its biochemical significance within sterol metabolism. However, these findings do not translate into recognized health benefits for humans consuming ergosta-5,7-dienol directly. There are no meta-analyses or systematic reviews evaluating its effects on human health outcomes, and no clinical guidelines recommend its intake for preventive or therapeutic health roles. Instead, ergosta-5,7-dienol remains a molecule of interest in basic science and industrial biotechnology rather than human nutrition.

For established nutrients such as vitamins and minerals, authoritative bodies like the NIH Office of Dietary Supplements provide recommended dietary allowances (RDAs) or adequate intakes for defined population groups. However, ergosta-5,7-dienol is not recognized as an essential nutrient in human nutrition, and no such intake recommendations exist. There is no evidence from dietary reference intake committees, including those at the NIH, that specifies required amounts for infants, children, adults, pregnant women, or older adults. The concept of a ‘need’ for ergosta-5,7-dienol in the human diet is therefore not applicable in the context of nutrient requirements. Consumption of ergosta-5,7-dienol occurs through dietary sources that contain fungal sterols, especially mushrooms. Studies examining sterol composition in mushrooms have quantified ergosta-5,7-dienol levels, indicating its presence typically at lower concentrations relative to ergosterol. For example, mushrooms such as oyster, shiitake, and button mushrooms contain ergosta-5,7-dienol in ranges from about 3.5 to 18 mg per 100 g dry weight, depending on species and cultivation conditions. These values reflect biochemical diversity in sterol profiles of fungi rather than dietary recommendations. Individuals do not need to ‘meet’ a specific intake of ergosta-5,7-dienol for health, as it does not serve an established nutritional function for humans. Its dietary relevance lies in its association with fungal foods and potential biochemical transformations (such as conversion to provitamin D4 under ultraviolet exposure) rather than a defined requirement for physiological processes. As such, typical dietary guidance emphasizes consumption of a variety of nutrient-dense foods to meet known macronutrient and micronutrient needs, and ergosta-5,7-dienol is not a targeted component of these recommendations.

Since ergosta-5,7-dienol is not an essential nutrient for humans and does not have an established physiological role, there are no clinical deficiency syndromes associated with inadequate intake. Deficiency symptoms are a concept linked to essential nutrients when their absence impairs biological function. In the absence of any recognized human metabolic requirement for ergosta-5,7-dienol, there are no specific symptoms, syndromes, or clinical manifestations attributable to ‘deficiency’ of this compound in the diet. Research into deficiencies pertains to nutrients like vitamins (e.g., vitamin D deficiency leading to rickets or osteomalacia) and minerals (e.g., iron deficiency leading to anemia), where lack of specific amounts disrupts enzymatic pathways or structural integrity of tissues. Ergosta-5,7-dienol does not figure in such frameworks because it does not participate in human metabolic pathways as a cofactor, structural molecule, or regulatory agent. Instead, its role is confined to fungal and microbial sterol biosynthesis. Thus, questions of deficiency prevalence, at‑risk populations, diagnostic criteria, and preventive strategies are not relevant to ergosta-5,7-dienol. It is included in food composition databases primarily to characterize sterol content of foods like mushrooms for research purposes, not to inform public health nutrition strategies. Health practitioners do not monitor ergosta-5,7-dienol levels in clinical settings, nor are there laboratory tests designed to assess its status in humans.

Ergosta-5,7-dienol occurs naturally in the sterol fraction of many edible mushrooms and fungal products. Studies that analyze sterol profiles in mushrooms have detected measurable amounts of ergosta-5,7-dienol across species. In an analysis of cultivated mushrooms, ergosta-5,7-dienol was present in all tested varieties, with concentrations ranging from approximately 3.5 mg to 18 mg per 100 g dry weight. Edible species such as oyster (Pleurotus ostreatus), shiitake (Lentinula edodes), button (Agaricus bisporus), enoki, maitake (Grifola frondosa), and chanterelle contained sterol fractions that included ergosta-5,7-dienol alongside ergosterol and other minor sterols. Foods like oyster mushrooms often displayed higher levels of ergosta-5,7-dienol relative to other mushroom types, reflecting differences in species‑specific sterol biosynthesis. Similarly, shiitake mushrooms, valued for their flavor and nutritional profile, also contain ergosta-5,7-dienol as part of their total sterol content. Button mushrooms, widely consumed globally, contain ergosta-5,7-dienol, albeit often at lower concentrations compared to oyster or shiitake species. Wild edible mushrooms, including chanterelles and porcini, likewise contain sterols, although specific ergosta-5,7-dienol quantities may vary based on habitat, maturity, and postharvest processing. Ergosta-5,7-dienol is a minor component in the broader category of phytosterols and mycosterols found in foods. Because it is not an essential nutrient with defined dietary recommendations, its presence is of interest mainly for food chemistry and sterol profiling rather than nutritional adequacy. Nevertheless, consuming a variety of edible mushrooms ensures exposure to ergosta-5,7-dienol as part of a diet rich in complex bioactive compounds and micronutrients.

There is limited research on the absorption and bioavailability of ergosta-5,7-dienol in humans, largely because it is not recognized as an essential nutrient. Its structural similarity to other sterols suggests that if absorbed, it would follow pathways akin to fungal sterols like ergosterol or plant phytosterols. In general, dietary sterols are absorbed at low efficiency in the human intestine because they compete with cholesterol for incorporation into mixed micelles and enterocytes. Dietary phytosterols, for example, are poorly absorbed compared with cholesterol due to active efflux mechanisms in enterocytes that limit their uptake. For ergosta-5,7-dienol, specific studies on human absorption are lacking. Research on related sterols and analogous compounds indicates that sterols with a 3β‑hydroxy group and unsaturated side chains are incorporated into micelles during digestion, though at varying efficiencies depending on molecular structure, food matrix, and presence of other lipids. Factors that enhance sterol absorption include concurrent dietary fat, which stimulates bile secretion and micelle formation. Conversely, high fiber intake and other dietary components that bind sterols can reduce absorption. Because ergosta-5,7-dienol is typically present at low concentrations in foods and is not an essential nutrient, detailed bioavailability studies have not been prioritized. Most sterol absorption research has focused on cholesterol and plant sterols with relevance to blood lipid management. Should future research investigate ergosta-5,7-dienol bioavailability, it would need to establish baseline absorption characteristics, influence of food matrix and processing, and potential metabolic fates in humans, including whether it contributes to systemic sterol pools or is excreted largely unchanged.

Because ergosta-5,7-dienol is not recognized as an essential nutrient and has no established dietary requirement or proven direct health benefits in humans, there is no rationale for taking supplements specifically to increase its intake. No authoritative guidelines suggest ergosta-5,7-dienol supplementation for any health condition, and there are no clinically validated dosing regimens or recommended forms. Sterol supplements that have been studied for health effects are typically plant sterols such as β-sitosterol, which have evidence for modest lowering of LDL cholesterol when taken at sufficient doses. Ergosta-5,7-dienol, by contrast, has not been the subject of clinical trials assessing health outcomes, and its presence in supplements is uncommon. In cases where ergosta-5,7-dienol might theoretically contribute to provitamin D4 yield upon UV conversion in foods, the more practical approach for vitamin D supplementation remains established forms like vitamin D2 and D3, which have documented efficacy in raising serum 25‑hydroxyvitamin D levels. Individuals interested in maximizing intake of sterols from foods can consume a variety of edible mushrooms, especially varieties with higher total sterol content. Supplements containing mushroom extracts often focus on other compounds such as polysaccharides or ergosterol content for potential antioxidant properties, not ergosta-5,7-dienol per se. As with any supplement, quality, purity, and regulation vary; professional healthcare guidance is recommended before starting any supplement, particularly for individuals with health conditions or taking medications.

Because ergosta-5,7-dienol is not used as a dietary supplement and is present in foods only in relatively low amounts, there are no established tolerable upper intake levels or toxicity thresholds for humans. The compound’s primary context of study is fungal metabolism rather than human nutrition, and it is not associated with recognized adverse effects from typical dietary exposure. Sterols in general, including those from plant sources, are considered safe components of the diet. Dietary phytosterols have been studied extensively and can modestly lower LDL cholesterol when consumed in gram‑level amounts; however, extremely high intakes can interfere with absorption of fat‑soluble vitamins in susceptible individuals. There is no evidence to suggest ergosta-5,7-dienol at amounts present in edible mushrooms poses similar risks. Most edible mushrooms provide sterols at levels that contribute only marginally to total dietary sterol intake. In food chemistry literature, analyses of mushroom sterol content quantify ergosta-5,7-dienol as one of several sterols without indicating harmful concentrations. Regulatory toxicology for fungal sterol components focuses on contaminants like mycotoxins rather than individual sterols. Thus, consumption of foods naturally containing ergosta-5,7-dienol within the context of a balanced diet poses no known toxicity risk, and no upper limit has been defined by health authorities.

There are no documented drug interactions that involve ergosta-5,7-dienol specifically. As a minor dietary sterol, it is not recognized as a pharmacologically active compound in humans, and its metabolic fate does not interact with common drug metabolism pathways. Most documented sterol‑drug interactions pertain to cholesterol metabolism and associated medications such as statins, which target human HMG‑CoA reductase, or bile acid sequestrants, which affect enterohepatic circulation of sterols. Ergosta-5,7-dienol does not feature in clinical guidelines for drug interaction monitoring. Fungal sterols such as ergosterol can influence antifungal pharmacology because certain antifungal drugs (e.g., azoles) target enzymes in the ergosterol biosynthesis pathway in fungi, thereby disrupting membrane integrity. However, these interactions are specific to fungal cells and do not translate to interactions with ergosta-5,7-dienol intake in humans. Nevertheless, individuals taking medications that affect lipid metabolism (e.g., statins, fibrates) should consult healthcare providers about dietary patterns, although sterol content of foods like mushrooms is unlikely to meaningfully alter drug effects.